Targeted Strategies for Today's Evolving Markets

MissionIR Blog

CoLucid Pharmaceuticals (CLCD) Presents at Rodman & Renshaw Conference

Founded in 2005, biopharmaceutical company CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) is focused on developing small molecules for the acute treatment of migraine headaches. The company’s lead product candidates are oral lasmiditan, an oral tablet for the acute treatment of migraine headaches in adults; and intravenous lasmiditan for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings. For more information, visit the company’s website at

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. For more information on Rodman & Renshaw, visit
This entry was posted in Rodman and Renshaw Conference. Bookmark the permalink.

Comments are closed.